Ophthalmology Times

SpyGlass Pharma reports positive 12-month phase I/II results for BIM-IOL System in glaucoma and ocular hypertension

Randomization (2:1:1) compared 78 mcg or 39 mcg BIM-IOL plus artificial tears versus standard monofocal IOL plus twice-daily timolol, with IOP change assessed at early visits. Mean IOP reduction at 12 ...
Ophthalmology Times

FDA approves Johnson & Johnson's TECNIS PureSee EDOF IOL

FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...
Healio

Eyhance IOL shows better tolerance of induced astigmatism than standard monofocal

Please provide your email address to receive an email when new articles are posted on . The Eyhance monofocal IOL showed better tolerance to induced astigmatism than a standard monofocal IOL. This can ...
Medical Device and Diagnostic Industry (MD+DI)

FDA Approves Johnson & Johnson's Breakthrough Cataracts Solution

The Tecnis PureSee IOL is the first FDA-approved extended depth of focus IOL maintaining contrast sensitivity comparable to ...

J&J wins FDA nod for Tecnis PureSee intraocular lens

Johnson & Johnson (JNJ) announced on Thursday that the U.S. Food and Drug Administration (FDA) approved its Tecnis PureSee intraocular lens (IOL), giving eye surgeons a new lens option for use in ...
Healio

Counseling patients on dysphotopsias necessary with presbyopia-correcting IOL use

Please provide your email address to receive an email when new articles are posted on . Part one of this series focused on balancing the three interrelated concepts of presbyopia-correcting or visual ...